Full text

Turn on search term navigation

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Low-grade and early Federation for Gynecology and Obstetrics (FIGO) stage endometrioid endometrial carcinomas (EEC) have an excellent prognosis. However, approximately 10% of patients develop recurrence, which cannot be correctly predicted at diagnosis. We evaluated myoinvasive patterns as a prognostic factor of relapse in low-grade, early-stage EEC. Two-hundred and fifty-eight cases were selected according to the following inclusion criteria: (i) endometrioid endometrial carcinomas, (ii) grade 1 or 2 with (iii) FIGO stage I or II, and (iv) clinical follow-up. Slides were reviewed to annotate the myoinvasive pattern present in each case (infiltrative glands, microcystic, elongated and fragmented –MELF-, broad front, adenomyosis-like and adenoma malignum). Microsatellite instability was studied by immunoexpression of mismatch repair proteins (MLH1, PMS2, MSH2, and MSH6). There were 29 recurrences (11.2%) among the 258 cases analysed. A predominant broad front myoinvasive pattern was significantly associated with tumour relapse (p = 0.003). The presence of a pattern of infiltrative glands (p = 0.001) and microsatellite instability (p = 0.004) were associated with lower disease-free survival, without having an impact on overall survival. Our observations suggest the potential value of the pattern of myoinvasion as a prognostic factor in low-grade, early-stage endometrioid endometrial carcinoma.

Details

Title
Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma
Author
Ruz-Caracuel, Ignacio 1   VIAFID ORCID Logo  ; Ramón-Patino, Jorge L 2 ; López-Janeiro, Álvaro 1 ; Yébenes, Laura 3 ; Berjón, Alberto 3   VIAFID ORCID Logo  ; Hernández, Alicia 4 ; Gallego, Alejandro 5 ; Heredia-Soto, Victoria 6 ; Mendiola, Marta 7 ; Redondo, Andrés 8 ; Peláez-García, Alberto 9 ; Hardisson, David 10   VIAFID ORCID Logo 

 Department of Pathology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain 
 Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain 
 Department of Pathology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain 
 Department of Obstetrics & Gynaecology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain 
 Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain; Translational Oncology Research Laboratory, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain 
 Translational Oncology Research Laboratory, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, 28046 Madrid, Spain 
 Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain; Center for Biomedical Research in the Cancer Network (Centro de Investigación Biomédica en Red de Cáncer, CIBERONC), Instituto de Salud Carlos III, 28046 Madrid, Spain 
 Department of Medical Oncology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain; Translational Oncology Research Laboratory, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, 28046 Madrid, Spain 
 Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain 
10  Department of Pathology, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain; Molecular Pathology and Therapeutic Targets Group, La Paz University Hospital (IdiPAZ), 28046 Madrid, Spain; Faculty of Medicine, Universidad Autónoma de Madrid, 28046 Madrid, Spain 
First page
1845
Publication year
2019
Publication date
2019
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2547582204
Copyright
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.